Skip to main content
Signal8

CDT Equity Inc. (CDT)

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

CDT Equity Inc. logo

CDT Equity Inc.

NASDAQ:CDTHealthcare
AH+5.56%$0.3800
Close$0.3600-4.51%
Mkt Cap$684K
EV-
Float1.76M
O/S1.9M
VOL317K sh
$ Vol$115K
RVOL0.13×
Inst Own0.0%
SI0.3%
Net Cash/Sh-
Dilution
CDT Equity Inc. logoNASDAQ:CDTAH$0.3800+5.56%
Short interest (FINRA)
0.3%
Oct 30 (18d)

Float 1.76M · Signal8 dilution snapshot · Nov 16, 2026

5.8K
Oct 30 (18d)prev 6.5K▼ 9.8%
1.00
Oct 30 (18d)prev 1.00– 0.0%
Borrow (IBKR)

The cost to borrow CDT shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
47.2%
Nov 16 (1d)prev 54.4%▼ 7.2 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

57.5K
Oct 30 (18d)prev 98.2K▼ 41.5%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20265.8K sh
Oct 15, 20266.5K sh
Sep 30, 20261.9K sh
Sep 15, 2026480 sh
Aug 31, 202684 sh
Latest fails to deliver
DateShares failed
Oct 30, 202657.5K sh
Oct 29, 202698.2K sh
Oct 28, 202650.2K sh
Oct 20, 202622.9K sh
Oct 19, 2026106.7K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202647.2%
Nov 13, 202654.4%
Nov 12, 202645.3%
Nov 11, 202643.7%
Nov 10, 202656.1%
90-session median 39.8%mean 39.9%range 8.0–67.5%

130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for CDT: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 116,825 CDT shares were sold short (0.33% of a 1.76M-share float, 1.00 days to cover).